Phase 2 Pneumococcal Vaccine Dose Study Completed by Inventprise

In a significant advancement in the field of biotechnology, Inventprise Inc. has successfully completed a crucial phase of its vaccine development program. The company's 25-valent pneumococcal conjugate vaccine (IVT PCV-25) has reached a milestone with the conclusion of its Phase 2 dose-ranging study in young adults across four Canadian sites. This development is pivotal in the quest to create an affordable and comprehensive pneumococcal conjugate vaccine (PCV) that offers extensive coverage against various serotypes.

Pneumococcal diseases, including pneumonia, sepsis, meningitis, and ear infections, pose a significant threat, particularly to children under five and adults over 65. The pneumococcus bacterium is linked to approximately 300,000 child deaths annually. Current PCVs protect against a limited range of serotypes, leaving room for improvement. Inventprise's IVT PCV-25 addresses this gap by covering 25 serotypes, potentially offering protection against additional deadly strains not covered by existing vaccines.

The Phase 2 study, sponsored by Inventprise in partnership with PATH and various Canadian research centers, is assessing the safety and efficacy of three different dosages of IVT PCV-25 in comparison to Prevnar20®. The study involves 220 participants aged between 18 and 49 and focuses on adverse events and antibody responses. Positive outcomes will facilitate the progression to Phase 2 trials in infants, scheduled for mid-2024, and older adults later in the year.

Manufacturing of the IVT PCV-25 vaccine is taking place at Inventprise's state-of-the-art facilities in Washington State, with funding provided by the Bill & Melinda Gates Foundation. Yves Leurquin, President & CEO of Inventprise, acknowledges the complexity of PCVs and the challenges in increasing serotype coverage and production capacity. However, the company has made strides in overcoming these obstacles through optimized formulations and manufacturing processes.

Dr. Subhash Kapre, Executive Chairman of Inventprise, expresses optimism about the vaccine's potential to provide enhanced immune responses and broader protection for children globally. Dr. Joanne Langley, principal investigator at the Canadian Center for Vaccinology, highlights the importance of the study in evaluating the vaccine's safety and efficacy, noting the continued prevalence of pneumococcal diseases due to unaddressed serotypes.

Inventprise Inc. is a biopharmaceutical company dedicated to developing vaccines against infectious diseases, with a focus on invasive pneumococcal disease. The company's platform technologies aim to induce broad and durable protection against various pathogenic strains. Inventprise's pipeline includes investigational vaccines for group B streptococcus (GBS) and Shigella, reflecting its commitment to advancing novel, affordable, and impactful vaccines globally.

The company was founded by Dr. Subhash Kapre in 2012 with the vision of providing life-saving interventions, especially to low and middle-income countries. Inventprise operates from facilities in Redmond and Woodinville, Washington, and continues to drive innovation in the vaccine development space.